Hormone replacement therapy with estradiol and drospirenone: an overview of the clinical data.
A new form of continuous combined hormone replacement therapy has become available that contains estradiol and drospirenone as the progestogen component. Drospirenone is a synthetic progestogen, the only one in hormone replacement therapy in the UK that possesses clinically relevant anti-mineralocorticoid activity. The combination of estradiol and drospirenone has been shown to provide relief from estrogen-deficiency symptoms of the menopause. It also helps to prevent osteoporosis in postmenopausal women by increasing bone density. Further, it has been shown to provide protection against endometrial hyperplasia associated with unopposed estrogen therapy.
Whitehead
Malcolm
M
King's College Hospital, London, UK. malcolm.whitehead@btconnect.com
D000368:Aged; D000736:Androstenes / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004714:Endometrial Hyperplasia / Q000473:pathology / Q000517:prevention & control*; D004958:Estradiol / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D020249:Hormone Replacement Therapy / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D008593:Menopause / Q000187:drug effects / Q000502:physiology; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016896:Treatment Outcome; D006113:United Kingdom
D000736:Androstenes; D004958:Estradiol; C035144:drospirenone